Comparative analysis of prognosis and gene expression in prostate cancer patients with site-specific visceral metastases
CONCLUSION: Patients diagnosed with mPCa and presenting with liver and/or lung metastases exhibit poorer prognoses. SCGB3A1, identified as a tumor suppressor gene, may contribute to the better survival prognosis observed in patients with prostate cancer lung metastases compared to those with liver metastases. The gene expression profiles in these two specific metastatic sites reveal a combination of both heterogeneity and homogeneity.PMID:38433022 | DOI:10.1016/j.urolonc.2024.01.032
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Peng Zhang Tieding Chen Ming Yang Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Databases & Libraries | Epidemiology | Genetics | Liver | Prostate Cancer | Respiratory Medicine | Study | Urology & Nephrology